Meet the host of Evidence Based Retina
Rishi P. Singh, MD, FASRS, is the Chair of the Department of Ophthalmology at Mass General Brigham, overseeing ophthalmology across Massachusetts Eye and Ear, Massachusetts General Hospital, Brigham and Women’s Hospital, and affiliated sites. He is also a Professor of Ophthalmology at Harvard Medical School.
Previously, Dr. Singh served as Vice President and Chief Medical Officer at Cleveland Clinic Martin Health in Stuart, Florida, and as a staff surgeon at the Cleveland Clinic, where he was also Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio.
He received both his undergraduate degree in medical science and his medical degree from Boston University, completing his internship at Tufts University. Dr. Singh went on to complete his ophthalmology residency at the Massachusetts Eye and Ear Infirmary/Harvard Medical School and a medical and surgical vitreoretinal fellowship at the Cole Eye Institute at the Cleveland Clinic.
He is the founder and past president of the Retina World Congress, chairs some of the largest continuing medical education meetings in retina, and serves on editorial boards and review panels for major ophthalmology journals. His leadership has extended into digital innovation, having helped lead enterprise-wide implementation of clinical technologies, including Epic modules, digital informed consent, and patient-facing kiosks.
Dr. Singh has received multiple accolades for his contributions to ophthalmic research and innovation, including the Alpha Omega Alpha Research Award, the American Society of Retina Specialists Young Investigator Award, and the J. Donald Gass Beacon of Sight Award. He also leads The Center for Ophthalmic Bioinformatics, a research initiative focused on leveraging big data and artificial intelligence to advance understanding and treatment of retinal disease.
More about the channel
Through video interviews, case reports, and articles, Evidence Based Retina will explore the latest in retinal research, diagnostics, and therapeutics, including new drugs, devices, and surgical techniques.
Presented through short, easily digestible segments with today’s top retina specialists, we will deliver clear, practical, and timely insights, always with one question in mind: “What does this mean for your patients?”
We will do this through:
- Peer-to-peer discussions on the latest retina research, studies, and trials.
- Case discussions from fellows and residents of the Mass Eye and Ear Infirmary.
- In-depth conversations with industry leaders from the companies that are developing innovative retinal therapeutics and surgical options.
What you can expect from Evidence Based Retina
Over the course of 2026, we will be covering a wide variety of relevant topics, including (but not limited to):
- Expanded indications for aflibercept 8mg
- How to use multimodal retinal imaging and AI to identify neurocognitive disease
- Clinical pearls for transitioning to flow-based vitrectomy
- Photobiomodulation therapy as a noninvasive approach to retinal disease
- Large epiretinal amniotic membrane patch (AMP) for refractory macular holes
- Latest findings from pegcetacoplan trials for geographic atrophy
- PVR pharmacotherapy
This channel is proud to serve as a trusted forum to help specialists, fellows, and researchers stay informed and up-to-date in the rapidly changing retina landscape. Thank you for joining us.
